期刊文献+

皮秒翠绿宝石激光点阵模式治疗黄褐斑疗效观察 被引量:4

Efficacy of the Fractional Picosecond Alexandrite Laser in the Treatment of Melasma
下载PDF
导出
摘要 目的:观察皮秒翠绿宝石激光点阵模式治疗黄褐斑的疗效及安全性。方法:分析在笔者科室进行皮秒翠绿宝石激光点阵模式治疗并随访3次以上的23例黄褐斑患者资料,利用黄褐斑面积及严重程度评分(Melasma Area and Severity Index,MASI)和医生整体评价法(Physician Global Assessment,PGA)对疗效进行评估,并记录不良反应。结果:23例黄褐斑患者经过3次治疗后,平均MASI评分较治疗前下降3.38±4.37,差异有统计学意义(P=0.001)。其中15例采用光斑6mm,能量密度0.71J/cm^2治疗,8例采用光斑8mm,能量密度0.4J/cm^2治疗,两组MASI评分较治疗前均有统计学意义(P=0.009,P=0.034),但两组比较,差异无统计学意义(P=0.452)。此外,根据PGA评分,3次治疗后黄褐斑为轻度改善。不良反应主要表现为轻微的红斑。结论:皮秒翠绿宝石激光点阵模式治疗黄褐斑安全、有效。 Objective To investigate the efficacy and adverse reactions of the fractional picosecond Alexandrite laser in melasma treatment. Methods The patients with melasma treated with the fractional mode of picosecond Alexandrite laser in our department and followed up for more than three times were retrospectively analyzed. The efficacy was evaluated by the Melasma Area and Severity Index (MASI) and the Physician Global Assessment (PGA). Related adverse reactions were documented in detail. Results A total of 23 patients with melasma were analyszed in our study. After 3 treatments, the MASI score decreased by 3.38±4.37, and the difference was statistically significant (P =0.001). Among them, 15 were treated with a 6-mm spot size and energy density of 0.71 J /cm^2, 8 were treated with an 8-mm spot size and energy density of 0.4 J /cm^2. The changes of their MASI score in each group were statistically significant (P =0.009 and P =0.034 respectively), but the differences between the both groups were not statistically significant (P =0.452). Besides, according to the PGA score, the melasma was slightly improved with 3 treatments of picosecond Alexandrite laser. Adverse reactions were mainly characterized by mild erythema. Conclusion The fractional picosecond Alexandrite laser with a diffractive lens array is safe and effective in the treatment of melasma.
作者 张孟丽 张二佳 黄玉清 林彤 ZHANG Meng-li;ZHANG Er-jia;HUANG Yu-qing;LIN Tong(Department of Cosmetic Laser Surgery,Hospital of Dermatology,Chinese Academy of Medical Sciences, Peking Union Medical College, Nanjing 210042, Jiangsu,China)
出处 《中国美容医学》 CAS 2019年第5期4-7,共4页 Chinese Journal of Aesthetic Medicine
基金 中国医学科学院医学与健康科技创新工程重大协同创新项目(CIFMS-2017-12M-1-017)
关键词 黄褐斑 皮秒 翠绿宝石激光 点阵激光 衍射微透镜阵列技术 melasma picosecond alexandrite laser fractional laser diffractive Lens array
  • 相关文献

参考文献3

二级参考文献47

  • 1Njoo MD,Das PK,Bos JD,et al.Association of the Kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris.Arch Dermatol,1999,135(4):407-413.
  • 2Hamzavi I,Jain H,McLean D,et al.Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool:the Vitiligo Area Scoring Index.Arch Dermatol,2004,140(6):677-683.
  • 3Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol, 2002, 29 (8): 539- 540.
  • 4Taylor SC, Torok H, Jones T, etal. Efficacy and safety of a new triplecombination agent for the treatment of facial melasma. Cutis, 2003, 72 (1): 67-72.
  • 5Ferreira CT, Hassun K, Sittart A, et al. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol, 2007, 6 (1): 36-39.
  • 6Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05% ) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasrna. Br J Dennatol, 2008, 159 (3): 697.
  • 7Keeling J, Cardona L, Benitez A, et al. Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature. Cutis, 2008, 81 (2): 179.
  • 8Cestari T, Arellano I, Hexsel D, et al. Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol, 2009, 23 (7): 760-772 .
  • 9Weiss JS, Shavin J S, Nighland M, et al. Tretinoin microsphere gel 0.1% for photodamaged facial skin: a placebo-controlled trial. Cutis, 2006, 78 (6): 426-432.
  • 10Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol, 2003, 49 (1): 83-90.

共引文献432

同被引文献62

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部